Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Nebraska: - Nebraska Cancer Specialists/Oncology Hematology West PC - MECC — Omaha, Nebraska
- Nebraska Methodist Hospital — Omaha, Nebraska
- Oncology Associates PC — Omaha, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Nebraska: - Nebraska Medicine-Bellevue Medical Center — Bellevue, Nebraska
- Nebraska Medicine — Omaha, Nebraska
- Nebraska Medicine - Village Pointe — Omaha, Nebraska
- University Of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Nebraska: - NHO Revive Research Institute, LLC — Lincoln, Nebraska
- NHO Support Center — Lincoln, Nebraska
- Cancer Partners of Nebraska — Lincoln, Nebraska
Phase 3 Recruiting Industry
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…
Sponsor: Pfizer
NCT ID: NCT06758401
Sites in Nebraska: - Oncology Hematology West, PC dba Nebraska Cancer Specialists - Fremont — Fremont, Nebraska
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island — Grand Island, Nebraska
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional — Grand Island, Nebraska
- Kearney Cancer Center — Kearney, Nebraska
- Cancer Partners of Nebraska — Lincoln, Nebraska
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Nebraska: - Research Site — Lincoln, Nebraska
Phase 3 Recruiting Network
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Nebraska: - Research Site — Grand Island, Nebraska
- Research Site — Omaha, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in Nebraska: - NHO Revive Research Institute — Lincoln, Nebraska
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Nebraska: - Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC) — Hastings, Nebraska
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in Nebraska: - Research Site — Lincoln, Nebraska
Phase 3 Recruiting Industry
This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Sponsor: Daiichi Sankyo
NCT ID: NCT06203210
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Industry
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival w…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07472517
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Nebraska: - University of Nebraska Medical Center Buffet Cancer Center — Omaha, Nebraska
Phase 2 Recruiting Industry
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…
Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each othe…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06162221
Sites in Nebraska: - Nebraska Cancer Specialist — Grand Island, Nebraska
Phase 2 Recruiting Industry
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combinati…
Sponsor: AstraZeneca
NCT ID: NCT05061550
Sites in Nebraska: - Research Site — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naï…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04165070
Sites in Nebraska: - Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031) — Omaha, Nebraska
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in Nebraska: - USA14-0 — Lincoln, Nebraska
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared …
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06057935
Sites in Nebraska: - University of Nebraska (Data collection only) — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295…
Sponsor: Accent Therapeutics
NCT ID: NCT06799065
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Federal
Randomized phase 2, multicenter, biomarker directed clinical trial with a safety lead-in to assess the efficacy of Stenoparib plus Temozolomide (TMZ) in relapsed Small Cell Lung Cancer patients. Participants will receive either a combinati…
Sponsor: VA Office of Research and Development
NCT ID: NCT06681220
Sites in Nebraska: - Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumo…
Sponsor: Molecular Partners AG
NCT ID: NCT07278479
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Nebraska: - Oncology Hematology West, PC dba Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1 Recruiting Industry
The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of \[177Lu\]Lu-DWJ155 and the safety and imaging properties of \[68Ga\]Ga-DWJ155 in patients with histologically or c…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07660055
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska